Cheng Han Ng (@ChengHanNg) header
Cheng Han Ng (@ChengHanNg) profile picture

Physician, Biotech & Researcher of Metabolic Diseases | RT =/ Support

Right Upper Quadrant
Joined January 2021
Photo by Cheng Han Ng (@ChengHanNg)Photo by Cheng Han Ng (@ChengHanNg)Photo by Cheng Han Ng (@ChengHanNg)Photo by Cheng Han Ng (@ChengHanNg)Photo by Cheng Han Ng (@ChengHanNg)Photo by Cheng Han Ng (@ChengHanNg)Photo by Cheng Han Ng (@ChengHanNg)Photo by Cheng Han Ng (@ChengHanNg)Photo by Cheng Han Ng (@ChengHanNg)Photo by Cheng Han Ng (@ChengHanNg)
#LiverTwitter abit late to the party, but glad to be part of the Stanford Top 2% list for 3 years in a row. This is not an individual effort, but rather a team based effort from all my fellow collaborators, colleagues and administrations that allow it to happen ❤️
1
11
351
#Livertwitter Muscle health is an important aspect with the onset of the GLP wave, and I am happy to share our latest paper in #metabolism on the pharmacological treatments for older adults! sciencedirect.com/science/ar…
3
12
651
昨年12月に佐賀高橋先生と立ち上げた #肝創 は、私にとって最もワクワクするプロジェクトの一つです。純粋な好奇心と善意から始まった、シンガポール🇸🇬と日本🇯🇵の研究交流への挑戦。「うまくいかない」と言われ続けましたが、今では医学生4名以上、若手医師4名がこのモデルで学び、活動しています。
2
7
575
Happy to finally see this study online. As we move beyond just looking at the liver alone, lipid lowering therapies for #PrimaryPrevention remains an important concept for #metabolic heath sciencedirect.com/science/ar…
1
14
601
#LiverTwitter and again, I couldn’t have done this without my friends, collaborators and team. 🥹 grateful to be ranked in the top 0.5% of the world again ❤️. More to come as we expand the liver team!
1
1
8
358
#LiverTwitter While im honored to be part of the list, and of course grateful to my friends and collaborators... I think theres too many list today 🤣
1
8
514
#LiverTwitter Happy to share our latest paper from the #CORE consortium, an Asia Pacific led initiative to understand compensated liver cirrhosis. Our latest paper explore how statin reduces the risk of hepatic decompensation and LRE @hepinternation1. link.springer.com/article/10…
2
6
13
580
#LiverTwitter excited to share our latest study using plain 2D ultrasound and #AI to reproduce #VCTE like results. The CNN model demonstrated good agreement with FAST and moderate agreement with AGILE 3+. onlinelibrary.wiley.com/doi/…
1
3
1
7
474
Excited to share our systematic review and meta-analysis on the prevalence of cancer across cardiovascular and cardiometabolic conditions, published pubmed.ncbi.nlm.nih.gov/4274…! 🫀🎗️📊A step toward better understanding the intersection of cancer and CVM health.
1
6
262
Proud to share our new review on sex-specific biology and the clinical implications of MASLD in women. We highlight how biological and hormonal differences may shape disease and why a more sex-specific approach to MASLD is needed link.springer.com/article/10…
1
6
231
#liverTwitter Proud to see the CORE database we built already generating meaningful insights. Our latest study uses CORE (23 centres now) to model the natural hx of decompensation, an exciting first step toward answering important clinical questions. journals.lww.com/hepcomm/ful…
1
6
13
593
Replying to @APASLnews
@APASLnews extremely thankful for the invitation to share at APASL STC Kumamoto on the Liver-Muscle axis. 💪 This is a growing topic of interest given the two organs are large reservoir of glucose storage. Thank you again to Prof Tanaka, and Prof Kawaguchi. ❤️
2
4
175
I’m excited to share our new study in @AJConline. We compared PREVENT and ASCVD-PCE for predicting cardiovascular mortality in US adults with MASLD using nationally representative data and competing-risk analysis. ajconline.org/article/S0002-…
1
6
296
肝創研究会のウェブサイトを公開しました! 私たちは、肝疾患研究を起点に、シンガポールと日本の研究交流を促進し、将来はより幅広い分野へ連携を広げることを目指します。新たなつながり、共同研究、発見が生まれる場を、皆さんと共に築いていければと思います。 livermetabolismlab.org/#ja
1
2
1
5
1,235
I have done many exams in my life, but never had I been so happy to see a PASS 😂😂😂 @NoureddinMD one step closer to coming to the states 🤣
1
10
702
肝創グループは高橋先生と私が立ち上げました。今では日本の若手医師が世界とつながる場です。堤先生(久留米)、上野先生(京都)、野上先生(横浜市大) は中心メンバー。研究は個人ではなく、皆の未来を拓くためにあると思います。
1
6
304
🚨Excited to share our latest work from our CORE Consortium exploring predictors of decompensation and mortality in compensated cirrhosis where ee evaluated the role of synthetic and cholestatic liver function markers in risk stratification! hbsn.amegroups.org/article/v…
1
6
1
6
1,023
Sharing our recent publication examining delisting from liver transplant waitlists in the context of clinical improvement. In this study, we evaluate the concept of “recompensation” in cirrhosis and its potential role as a clinically meaningful endpoint journals.lww.com/transplantj…
6
7
618
🧬 Excited to share our new review in npj Gut and Liver! We map the genetic, metabolic, histologic & environmental diversity of MASLD—and how this heterogeneity can shape precision-medicine strategies for risk stratification & targeted therapy. 🔗 doi.org/10.1038/s44355-026-0…
3
12
582
just shy of a month to MetaboAsia.com, a NUS premier sharing of metabolic diseases with academia, biotech, and clinicians! Sign up is totally free! DATE: 8 July 2026 VENUE: NUS Medicine, LT 35, MD6
2
4
354